The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma

Pediatric Drugs

Volumn 16, Issue 6, 2014, Pages 503-512

  Xiao, Xin ^a   Wang, Wei ^b   Wang, Zhen ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; TOPOTECAN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; TAXOID;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; DRUG MEGADOSE; EMBASE; HUMAN; MEDLINE; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VALIDATION STUDY; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; MORTALITY; NEOPLASM RECURRENCE, LOCAL; SECONDARY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; ETOPOSIDE; HUMANS; IFOSFAMIDE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; TAXOIDS;

EID: 84919907431     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-014-0095-z     Document Type: Review

References (48)

1. Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther. 2007;7(2):169–81. doi:10.1586/14737140.7.2.169.
2. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–90.
3. Campanacci M, Cervellati G. Osteosarcoma: a review of 345 cases. Ital J Orthop Traumatol. 1975;1(1):5–22.
4. Cohen P. Osteosarcoma of the long bones. Clinical observations and experiences in the Netherlands. Eur J Cancer. 1978;14(9):995–1004.
5. Mulder JD, Schütte H, Kroon H, Taconis W. Radiologic atlas of bone tumors. Amsterdam: Elsevier; 1993.
6. Unni KK. Dahlin’s bone tumors: general aspects and data on 11,087 cases. Philadelphia: Lippincott-Raven; 1996.
7. Uribe-Botero G, Russell WO, Sutow WW, Martin RG. Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol. 1977;67(5):427–35.
8. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9(8):893–9.
9. Giuliano AE, Feig S, Eilber FR. Changing metastatic patterns of osteosarcoma. Cancer. 1984;54(10):2160–4.
10. Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, Link MP. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol. 1991;9(4):600–5.
11. Jaffe N, Smith E, Abelson HT, Frei E 3rd. Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol. 1983;1(4):251–4.
12. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32(6):423–36. doi:10.1016/j.ctrv.2006.05.005.
13. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer. 1995;75(5):1084–93.
14. Marina NM, Pratt CB, Rao BN, Shema SJ, Meyer WH. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer. 1992;70(11):2722–7.
15. Meyers PA, Heller G, Vlamis V. Osteosarcoma of the extremities: chemotherapy experience at Memorial Sloan-Kettering. Cancer Treat Res. 1993;62:309–22.
16. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994;12(9):1849–58.
17. Petrie A, Sabin C. Medical statistics at a glance. 3rd ed. Chichester: Wiley-Blackwell; 2009.
18. Michelagnoli MP, Lewis IJ, Gattamaneni HR, Bailey CC, Lashford LS. Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma. Br J Cancer. 1999;79(7–8):1174–8. doi:10.1038/sj.bjc.6690187.
19. Kung FH, Pratt CB, Vega RA, Jaffe N, Strother D, Schwenn M, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer. 1993;71(5):1898–903.
20. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5(8):1191–8.
21. Gentet JC, Brunat-Mentigny M, Demaille MC, Pein F, Avet-Loiseau H, Berger C, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer. 1997;33(2):232–7.
22. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20(2):426–33.
23. Yalcin S, Gullu I, Barista I, Tekuzman G, Ozisik Y, Celik I, et al. Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy. Cancer Invest. 1998;16(5):297–302.
24. Kung FH, Desai SJ, Dickerman JD, Goorin AM, Harris MB, Inoue S, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol. 1995;17(3):265–9.
25. Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005;44(4):338–47. doi:10.1002/pbc.20227.
26. Berger M, Grignani G, Ferrari S, Biasin E, Brach del Prever A, Aliberti S et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer. 2009;115(13):2980-7. doi:10.1002/cncr.24368.
27. Mantadakis E, Herrera L, Leavey PJ, Bash RO, Winick NJ, Kamen BA. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study. J Clin Oncol. 2000;18(13):2576–81.
28. Rodriguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, Pappo AS, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol. 2002;24(4):250–5.
29. Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012;17(3):321. doi:10.1634/theoncologist.2010-0265.
30. Gosiengfiao Y, Reichek J, Woodman J, Ben-Ami T, Walterhouse D. Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children’s Memorial Hospital. J Pediatr Hematol Oncol. 2012;34(2):e63–5. doi:10.1097/MPH.0b013e3182331ee8.
31. Lee EM, Rha SY, Lee J, Park KH, Ahn JH. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Cancer Chemother Pharmacol. 2012;69(3):635–42. doi:10.1007/s00280-011-1742-5.
32. Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 2009;31(10):723–9. doi:10.1097/MPH.0b013e3181b2598c.
33. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113(2):419–25. doi:10.1002/cncr.23586.
34. Qi WX, He AN, Tang LN, Shen Z, Lin F, Yao Y. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol. 2012;42(5):427–31. doi:10.1093/jjco/hys030.
35. Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 2012;59(5):854–8. doi:10.1002/pbc.24101.
36. Saylors RL 3rd, Stewart CF, Zamboni WC, Wall DA, Bell B, Stine KC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16(3):945–52.
37. Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19(15):3463–9.
38. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7(1):126–31.
39. Klein HO, Wickramanayake PD, Coerper C, Christian E, Pohl J, Brock N. High-dose ifosfamide and mesna as continuous infusion over five days–a phase I/II trial. Cancer Treat Rev. 1983;10 Suppl A:167–73.
40. Magrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V, Miser J. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol. 1986;18(Suppl 2):S25–8.
41. Marti C, Kroner T, Remagen W, Berchtold W, Cserhati M, Varini M. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985;69(1):115–7.
42. Rodriguez V, McCredie KB, Keating MJ, Valdivieso M, Bodey GP, Freireich EJ. Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treat Rep. 1978;62(4):493–7.
43. Scheulen ME, Niederle N, Bremer K, Schutte J, Seeber S. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients. Cancer Treat Rev. 1983;10 Suppl A:93–101.
44. Stuart-Harris R, Harper PG, Kaye SB, Wiltshaw E. High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev. 1983;10 Suppl A:163–4.
45. Yazigi R, Wild R, Madrid J, Arraztoa J. Ifosfamide treatment of advanced ovarian cancer. Obstet Gynecol. 1984;63(2):163–6.
46. Pratt CB, Horowitz ME, Meyer WH, Etcubanas E, Thompson EI, Douglass EC, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987;71(2):131–5.
47. Grem JL, King SA, Wittes RE, Leyland-Jones B. The role of methotrexate in osteosarcoma. J Natl Cancer Inst. 1988;80(9):626–55.
48. Rosen G. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma. Cancer Treat Res. 1993;62:49–54.